Galectin Therapeutics INC 8-K Filing

Ticker: GALT · Form: 8-K · Filed: Nov 10, 2025 · CIK: 1133416

Galectin Therapeutics INC 8-K Filing Summary
FieldDetail
CompanyGalectin Therapeutics INC (GALT)
Form Type8-K
Filed DateNov 10, 2025
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Galectin Therapeutics INC (ticker: GALT) to the SEC on Nov 10, 2025.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (nge on which registered Common Stock $0.001par value per share GALT The Nasdaq).

How long is this filing?

Galectin Therapeutics INC's 8-K filing is 2 pages with approximately 639 words. Estimated reading time is 3 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 639 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2025-11-10 07:56:04

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On November 10, 2025, Galectin Therapeutics Inc. (the "Company") issued a press release announcing that it presented its NAVIGATE trial results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting and posted to its website an updated Corporate Presentation, furnished hereto as Exhibit 99.1 and Exhibit 99.2, respectively. and incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information furnished under this Item 7.01 of this Current Report on Form 8-K and the exhibits furnished hereto are deemed to be "furnished" and shall not be deemed "filed" for the purpose of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information and exhibits be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended. This Current Report on Form 8-K and Exhibits 99.1 and 99.2 hereto contain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibits 99.1 and 99.2 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Exhibit Description 99.1 Press release dated November 10, 2025 99.2 Galectin Therapeutic Inc. Corporate Presentation, updated November 10, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) - 2 -

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Galectin Therapeutics Inc. Date: November 10, 2025 By: /s/ Jack W. Callicutt Jack W. Callicutt Chief Financial Officer - 3 -

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing